A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma

Fathima Zumla Cader,Xihao Hu,Walter L. Goh,Kirsty Wienand,Jing Ouyang,Elisa Mandato,Robert Redd,Lee N. Lawton,Pei-Hsuan Chen,Jason L. Weirather,Ron C. J. Schackmann,Bo Li,Wenjiang Ma,Philippe Armand,Scott J. Rodig,Donna Neuberg,X. Shirley Liu,Margaret A. Shipp

DOI: https://doi.org/10.1038/s41591-020-1006-1

IF: 82.9

2020-08-10

Nature Medicine

Abstract:PD-1 blockade is highly effective in classical Hodgkin lymphomas (cHLs), which exhibit frequent copy-number gains of <i>CD274</i> (<i>PD-L1</i>) and <i>PDC1LG2</i> (<i>PD-L2</i>) on chromosome 9p24.1. However, in this largely MHC-class-I-negative tumor, the mechanism of action of anti-PD-1 therapy remains undefined. We utilized the complementary approaches of T cell receptor (TCR) sequencing and cytometry by time-of-flight analysis to obtain a peripheral immune signature of responsiveness to PD-1 blockade in 56 patients treated in the CheckMate 205 phase II clinical trial (<a href="https://clinicaltrials.gov/ct2/show/NCT02181738">NCT02181738</a>). Anti-PD-1 therapy was most effective in patients with a diverse baseline TCR repertoire and an associated expansion of singleton clones during treatment. CD4⁺, but not CD8⁺, TCR diversity significantly increased during therapy, most strikingly in patients who had achieved complete responses. Additionally, patients who responded to therapy had an increased abundance of activated natural killer cells and a newly identified CD3⁻CD68⁺CD4⁺GrB⁺ subset. These studies highlight the roles of recently expanded, clonally diverse CD4⁺ T cells and innate effectors in the efficacy of PD-1 blockade in cHL.

biochemistry & molecular biology,cell biology,medicine, research & experimental

What problem does this paper attempt to address?

This paper aims to explore the peripheral immune characteristics of patients with classical Hodgkin lymphoma (cHL) in response to PD - 1 blockade therapy. Specifically, the researchers attempted to address the following questions:

1. **Determine the relationship between T - cell receptor (TCR) diversity of peripheral blood mononuclear cells (PBMCs) and treatment response in patients responding to PD - 1 blockade therapy**:
- The study found that patients with higher TCR diversity at baseline were more likely to achieve complete remission (CR) after PD - 1 blockade therapy. In particular, the TCR diversity of CD4+ T cells increased significantly during the treatment process, while this phenomenon was not observed in CD8+ T cells.

2. **Explore the clonal expansion of specific T - cell subsets after PD - 1 blockade therapy**:
- The study found that in patients with a good treatment response, less - differentiated monoclonal T cells (singleton clones) had greater expansion than differentiated non - monoclonal T cells (non - singleton clones). This indicates that the expansion of less - differentiated T cells during treatment may be associated with better treatment outcomes.

3. **Analyze the changes of different immune cell subsets in peripheral blood before and after PD - 1 blockade therapy**:
- Through mass cytometry (CyTOF) analysis, the researchers found that in patients responding to treatment, the numbers of activated natural killer (NK) cells and a newly identified CD3−CD68+CD4+GrB+ cell subset increased significantly. These changes may reflect the mechanism of action of PD - 1 blockade therapy in cHL.

In summary, through comprehensive analysis of TCR diversity, T - cell clonal expansion, and changes in different immune cell subsets in peripheral blood, this paper attempts to reveal the mechanism of action of PD - 1 blockade therapy in cHL patients and provide a theoretical basis for future clinical applications.